HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data)

Author:

Barré Tangui,Mercié Patrick,Lions Caroline,Miailhes Patrick,Zucman David,Aumaître Hugues,Esterle Laure,Sogni Philippe,Carrieri Patrizia,Salmon-Céron Dominique,Marcellin Fabienne,Salmon D.,Wittkop L.,Sogni P.,Esterle L.,Trimoulet P.,Izopet J.,Serfaty L.,Paradis V.,Spire B.,Carrieri P.,Valantin M. A.,Pialoux G.,Chas J.,Poizot-Martin I.,Barange K.,Naqvi A.,Rosenthal E.,Bicart-See A.,Bouchaud O.,Gervais A.,Lascoux-Combe C.,Goujard C.,Lacombe K.,Duvivier C.,Neau D.,Morlat P.,Bani-Sadr F.,Meyer L.,Boufassa F.,Autran B.,Roque A. M.,Solas C.,Fontaine H.,Costagliola D.,Piroth L.,Simon A.,Zucman D.,Boué F.,Miailhes P.,Billaud E.,Aumaître H.,Rey D.,Peytavin G.,Petrov-Sanchez V.,Levier A.,Usubillaga R.,Terris B.,Tremeaux P.,Katlama C.,Valantin M. A.,Stitou H.,Cacoub P.,Nafissa S.,Benhamou Y.,Charlotte F.,Fourati S.,Zaegel O.,Laroche H.,Tamalet C.,Callard P.,Bendjaballah F.,Le Pendeven C.,Marchou B.,Alric L.,Metivier S.,Selves J.,Larroquette F.,Rio V.,Haudebourg J.,Saint-Paul M. C.,De Monte A.,Giordanengo V.,Partouche C.,Martin A.,Ziol M.,Baazia Y.,Iwaka-Bande V.,Gerber A.,Uzan M.,Garipuy D.,Ferro-Collados M. J.,Nicot F.,Yazdanpanah Y.,Adle-Biassette H.,Alexandre G.,Molina J. M.,Bertheau P.,Chaix M. L.,Delaugerre C.,Maylin S.,Bottero J.,Krause J.,Girard P. M.,Wendum D.,Cervera P.,Adam J.,Viala C.,Vittecocq D.,Quertainmont Y.,Teicher E.,Pallier C.,Lortholary O.,Rouzaud C.,Lourenco J.,Touam F.,Louisin C.,Avettand-Fenoel V.,Gardiennet E.,Mélard A.,Ochoa A.,Blanchard E.,Castet-Lafarie S.,Cazanave C.,Malvy D.,Dupon M.,Dutronc H.,Dauchy F.,Lacaze-Buzy L.,Desclaux A.,Bioulac-Sage P.,Reigadas S.,Lacoste D.,Bonnet F.,Bernard N.,Hessamfar M.,J ,Paccalin F.,Martell C.,Pertusa M. C.,Vandenhende M.,Mercié P.,Pistone T.,Receveur M. C.,Méchain M.,Duffau P.,Rivoisy C.,Faure I.,Caldato S.,Bellecave P.,Tumiotto C.,Pellegrin J. L.,Viallard J. F.,Lazzaro E.,Greib C.,Majerholc C.,Brollo M.,Farfour E.,Devoto J. Polo,Kansau I.,Chambrin V.,Pignon C.,Berroukeche L.,Fior R.,Martinez V.,Abgrall S.,Favier M.,Deback C.,Lévy Y.,Dominguez S.,Lelièvre J. D.,Lascaux A. S.,Melica G.,Raffi F.,Allavena C.,Reliquet V.,Boutoille D.,Biron C.,Lefebvre M.,Hall N.,Bouchez S.,Rodallec A.,Le Guen L.,Hemon C.,Peyramond D.,Chidiac C.,Ader F.,Biron F.,Boibieux A.,Cotte L.,Ferry T.,Perpoint T.,Koffi J.,Zoulim F.,Bailly F.,Lack P.,Maynard M.,Radenne S.,Amiri M.,Valour F.,Augustin-Normand C.,Scholtes C.,Le-Thi T. T.,Van Huyen P. Chavanet M. Duong,Buisson M.,Waldner-Combernoux A.,Mahy S.,Rousseau A. Salmon,Martins C.,Galim S.,Lambert D.,Nguyen Y.,Berger J. L.,Hentzien M.,Brodard V.,Partisani M.,Batard M. L.,Cheneau C.,Priester M.,Bernard-Henry C.,de Mautort E.,Fischer P.,Gantner P.,Fafi-Kremer S.,Roustant F.,Platterier P.,Kmiec I.,Traore L.,Lepuil S.,Parlier S.,Sicart-Payssan V.,Bedel E.,Anriamiandrisoa S.,Pomes C.,Mole M.,Bolliot C.,Catalan P.,Mebarki M.,Adda-Lievin A.,Thilbaut P.,Ousidhoum Y.,Makhoukhi F. Z.,Braik O.,Bayoud R.,Gatey C.,Pietri M. P.,Le Baut V.,Rayana R. Ben,Bornarel D.,Chesnel C.,Beniken D.,Pauchard M.,Akel S.,Lions C.,Ivanova A.,Ritleg A.-S.,Debreux C.,Chalal L.,Zelie J.,Hue H.,Soria A.,Cavellec M.,Breau S.,Joulie A.,Fisher P.,Gohier S.,Croisier-Bertin D.,Ogoudjobi S.,Brochier C.,Thoirain-Galvan V.,Le Cam M.,Chalouni M.,Conte V.,Dequae-Merchadou L.,Desvallees M.,Gilbert C.,Gillet S.,Knight R.,Lemboub T.,Marcellin F.,Michel L.,Mora M.,Protopopescu C.,Roux P.,Tezkratt S.,Barré T.,Rojas T. Rojas,Baudoin M.,Di Beo M. Santos V.,Nishimwe M.,

Abstract

Abstract Background Thanks to direct-acting antivirals, hepatitis C virus (HCV) infection can be cured, with similar rates in HCV-infected and HIV–HCV co-infected patients. HCV cure is likely to foster behavioral changes in psychoactive substance use, which is highly prevalent in people living with HIV (PLWH). Cannabis is one substance that is very commonly used by PLWH, sometimes for therapeutic purposes. We aimed to identify correlates of cannabis use reduction following HCV cure in HIV–HCV co-infected cannabis users and to characterize persons who reduced their use. Methods We used data collected on HCV-cured cannabis users in a cross-sectional survey nested in the ANRS CO13 HEPAVIH cohort of HIV–HCV co-infected patients, to perform logistic regression, with post-HCV cure cannabis reduction as the outcome, and socio-behavioral characteristics as potential correlates. We also characterized the study sample by comparing post-cure substance use behaviors between those who reduced their cannabis use and those who did not. Results Among 140 HIV-infected cannabis users, 50 and 5 had reduced and increased their use, respectively, while 85 had not changed their use since HCV cure. Cannabis use reduction was significantly associated with tobacco use reduction, a decrease in fatigue level, paying more attention to one’s dietary habits since HCV cure, and pre-HCV cure alcohol abstinence (p = 0.063 for alcohol use reduction). Conclusions Among PLWH using cannabis, post-HCV cure cannabis reduction was associated with tobacco use reduction, improved well-being, and adoption of healthy behaviors. The management of addictive behaviors should therefore be encouraged during HCV treatment.

Funder

French National Agency for Research on Aids and Viral Hepatitis

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Virology,Molecular Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3